Azurity Pharmaceuticals

Azurity does not discover new molecules. It identifies FDA-approved drugs where a significant patient population—often pediatrics, geriatrics, or those with dysphagia—cannot use the standard tablet form. The firm reformulates these drugs into oral liquids, sprinkle capsules, chewables, or films, and files 505(b)(2) applications that rely partially on the reference drug's existing safety data rather than conducting entirely new clinical trials.

Azurity's portfolio concentrates on cardiovascular, central nervous system, and anti-infective categories. Notable products include Epaned (enalapril oral solution) for pediatric hypertension, Dyanavel XR (amphetamine) for ADHD, and Firvanq (vancomycin oral solution) for C. difficile-associated diarrhea. The Slayback acquisition added injectable and ophthalmic pipeline candidates.

Azurity is a privately held company. It has been backed by healthcare-focused private equity investors over multiple capital cycles, though current ownership stakes are not publicly disclosed. The company has grown through serial acquisitions, including the purchase of Silvergate Pharmaceuticals in 2021 and Slayback Pharma in 2023, suggesting continued investment support for consolidation in the specialty dosage-form space.

Azurity targets patient populations too small to attract major generic manufacturers. Developing a liquid formulation of a drug like enalapril requires taste-masking, stability testing, and bioequivalence work that represents a niche capability set. Once approved, the limited market size and manufacturing complexity create natural barriers to entry, allowing Azurity to avoid the volume-and-price competition that defines standard generics.

Azurity's commercial operations are concentrated in the United States. The Slayback Pharma acquisition included R&D facilities in Hyderabad, India, alongside a New Jersey-based development site, so the firm now has a transcontinental research footprint. Selling internationally remains limited, as 505(b)(2) approvals are jurisdiction-specific and many of Azurity's reference drugs have different regulatory statuses abroad.